Platinum doublet vs non‐platinum therapy
Progression‐free survival · people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
Platinum doublet probably leads to lower progression‐free survival compared with non‐platinum therapy (moderate certainty).
1 finding from 1 review
- Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable… 2023 · Cochrane Headline outcomes onlyHR 0.57 [0.42, 0.77]5 studies · 487 participantsModerate